EGFR and cancer: These drugs improve patient survival 6 by targeting receptor tyrosine kinase (RTK) aberrations in cancers, including epidermal growth factor receptor (EGFR), BRAF, anaplastic lymphoma kinase, RET, ROS1, and MET 7,8.